1. Mulcahy, D., Weeks, B. & Bradley, H.S. We have met the enemy... and he is us. Ewing Marion Kauffman Foundation,
http://www.kauffman.org/∼/media/kauffman_org/research%20reports%20and%20covers/2012 /05/we%20have%20met%20the%20enemy%20and%20he%20is%20us(1).pdf
(2012).
2. Ewing Marion Kauffman Foundation. Institutional limited partners must accept blame for poor long-term returns from venture capital, says new Kauffman report. Ewing Marion Kauffman Foundation,
http://www.kauffman.org/newsroom/2012/07/institutional-limited-partners-must-accept-blame-for-poor-longterm-returns-from-venture-capital-says-new-kauffman-report
(2012).
3. PricewaterhouseCoopers. Life sciences venture capital funding drops 14% during 2012, according to the MoneyTree report. PricewaterhouseCoopers,
http://www.pwc.com/us/en/press-releases/2013/2q-life-sciences-moneytree.jhtml
(2013).
4. Timmerman, L. Who's still active among the early-stage biotech VCs? Xconomy,
http://www.xconomy.com/national/2012/07/02/whos-still-active-among-the-early-stage-biotech-vcs
(2012).
5. PitchBook. 4Q 2013 Venture Capital Valuations & Trends Report. PitchBook,
http://pitchbook.com/4Q2013_VC_Valuations_and_Trends_Report.html
(2013).